DelveInsight’s ‘Scleroderma Pipeline Insights’ report lays down a holistic coverage of the available therapies, Scleroderma pipeline therapies in different developmental phases of clinical trials, key companies active in the Scleroderma pipeline domain, driving factors and restraints in the commercial launch of the Scleroderma pipeline therapies, and future trends.
Some of the key highlights from the Scleroderma Pipeline report:
Request for Sample to know which pharma company is expected to be at the forefront in the coming years @ Scleroderma Emerging Therapies and Forecast
The Scleroderma Pipeline report comprises detailed information on ongoing clinical trials, deals, mergers & acquisitions taking place in the domain, recent approvals and failures in space, and growth prospects across the Scleroderma domain.
Scleroderma Overview
Scleroderma is a group of rare diseases that leads to the hardening and tightening of the skin and connective tissues. There are 2 major types of Scleroderma: Localized Scleroderma that affects the skin and Systemic Scleroderma that affects blood circulation and internal organs as well as the skin. The condition appears to affect women more as compared to men. At present, there exists no cure for the disease; however, there are symptomatic treatment approaches available.
Discover more about the disease, treatments, and pipeline therapies @ Scleroderma Pipeline Assessment
Scleroderma Pipeline Drugs
Drug
Company
Phase
MoA
RoA
Lenabasum
Corbus Pharmaceuticals
III
Cannabinoid receptor CB2 agonists
Oral
Iloprost
Eicos Sciences
Epoprostenol agonists
Intravenous
KHK4827
Kyowa Kirin
Interleukin 17 receptor antagonists
Subcutaneous
ECCS-50
Cytori therapeutics
Cell replacements
EHP 101
Emerald Health Pharmaceuticals
II
Cannabinoid receptor CB2 agonists; Endothelial PAS domain-containing protein 1 inhibitors; Hypoxia-inducible factor 1 inhibitors; Peroxisome proliferator-activated receptor-gamma agonists
FT011
Certa Therapeutics
Platelet-derived growth factor inhibitors
Belumosudil
Kadmon Corporation
Rho-associated kinase inhibitors
Guselkumab
Janssen Pharmaceutical
Interleukin-23 subunit p19 inhibitors
Intravenous, Subcutaneous
FCX 013
Castle Creek Biosciences
I/II
Gene transference; Matrix metalloproteinase 1 replacements
Intradermal
VIB7734
Viela Bio
I
Dendritic cell inhibitors
NA
CM-101
Chemomab Therapeutics
Chemokine CCL24 inhibitors
AM1476
AnaMar
Serotonin 2B receptor antagonists
LMY-920
Luminary Therapeutics
Preclinical
Immunologic cytotoxicity; T lymphocyte replacements
Parenteral
CAN-10
Cantargia
Interleukin 1 inhibitors; Interleukin-33 inhibitors
hzVSF v13
ImmuneMed
Discovery
Immunomodulators; Virus replication inhibitors
Request for Sample to know more @ Scleroderma Pipeline Analysis, Key Companies, and Futuristic Trends
Scleroderma Therapeutics Assessment
The Scleroderma Pipeline report proffers an integral view of the Scleroderma emerging novel therapies segmented by Stage, Product Type, Route of Administration, Molecule Type, Target, and Mechanism of Action.
By Product Type
By Stage
By Molecule Type
By Route of Administration
By Mechanism of Action
By Targets
Scope of the Scleroderma Drug Pipeline Report
Coverage: Global
Key Players: Corbus Pharmaceuticals, Emerald Health Pharmaceuticals, Gesynta Pharma, Formation Biologics, Fibrocell Science, CSL Behring, ChemomAb, Luminary Therapeutics, Certa Therapeutics, Kadmon Corporation, Janssen Pharmaceutical, Horizon Therapeutics, Acceleron Pharma, Tvardi Therapeutics, BriaCell Therapeutics, Blade Therapeutics, Biosplice Therapeutics, AnaMar, Immunemed, Viela Bio among others.
Key Scleroderma Pipeline Therapies: Lenabasum, EHP 101, FT011, Belumosudil, Guselkumab, ECCS 50, KHK4827, SAR156597, Treprostinil, HZN-825, GS-248, Brentuximab Vedotin, C21, ARG201, Belumosudil, CAM2043, Tofacitinib, Sarilumab, FCX 013, VIB7734, AVID200 and several others.
Table of Contents
1
Report Introduction
2
Executive Summary
3
Scleroderma Disease Overview
4
Scleroderma Pipeline Therapeutics Comparative Analysis
5
Scleroderma Therapeutic Assessment
6
In-depth Commercial Assessment
7
Scleroderma – DelveInsight’s Analytical Perspective
8
In-depth Commercial Scleroderma Assessment
9
Scleroderma Collaboration Deals
10
Late Stage Scleroderma Products (Phase III)
10.1
Lenabasum: Corbus Pharmaceuticals
11
Mid-Stage Scleroderma Products (Phase II)
11.1
EHP 101: Emerald Health Pharmaceuticals
12
Early Stage Scleroderma Products (Phase I)
12.1
VIB7734: Viela Bio
13
Pre-clinical and Discovery Stage Scleroderma Products
13.1
LMY-920: Luminary Therapeutics
14
Inactive Scleroderma Pipeline Products
15
Key Scleroderma Products
16
Unmet Needs
17
Scleroderma Market Drivers and Barriers
18
Future Perspectives and Conclusion
19
Analyst Views
20
Key Scleroderma Companies
21
Appendix
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
For more insights, visit Pharma, Healthcare, and Biotech News
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +19193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/report-store/scleroderma-pipeline-insight